Published: 23 December 2021
Author(s): Collaborative group: MI study group
Section: Letter to the Editor
There is an unmet medical need to provide novel treatments with high efficiency and low side effects in patients with sarcoidosis resistant to glucocorticoids or second-line therapies (methotrexate, TNFα inhibitors), or who cannot tolerate them [1].
